Collaborations Pharmaceuticals, Inc. And Texas Biomed Announce NIH Award to Develop a Treatment for Ebola
The National Center for Advancing Translational Sciences (NCATS) recently awarded $596,533.00 to Collaborations Pharmaceuticals, Inc. (CPI) to initiate a partnership with Texas Biomedical Research Institute aimed at repurposing an antimalarial for...
10-Nov-2016 8:00 AM EST Add to Favorites
Texas Biomedical Research Institute Staff Scientist recently awarded a grant from the National Institutes of Health to study and identify molecular mechanisms underlying early atherosclerosis.
25-Oct-2016 12:00 PM EDT Add to Favorites
STEM CELLS Translational Medicine published the work of San Antonio scientists aiming to develop a more effective method for delivering neural stem cells to the brain in an effort to move forward stem cell therapies to treat neurological disorders.
18-Oct-2016 9:00 AM EDT Add to Favorites
Southwest National Primate Research Center (SNPRC) at Texas Biomedical Research Institute (Texas Biomed) was awarded more than $40 million for a National Institutes of to continue research programs using nonhuman primates (NHP) as part of the...
4-Aug-2016 9:05 AM EDT Add to Favorites
To support a coordinated, innovative approach to the development of an AIDS vaccine, Texas Biomedical Research Institute scientists, together with an international coalition of experts, have received a grant for $23 million from the National...
21-Jul-2016 10:15 AM EDT Add to Favorites
Dr. Tim Anderson at Texas Biomedical Research Institute and Dr. Phil LoVerde at the University of Texas Health Science Center at San Antonio have been awarded a $3.5 million grant over the next five years by the National Institutes of Health to...
7-Jun-2016 9:30 AM EDT Add to Favorites
HIV vaccine candidate has shown to generate more than 80% protection in groups of twelve female monkeys against high dose, repeated AIDS virus exposures during part of a preclinical study.
12-Apr-2016 10:30 AM EDT Add to Favorites
A recent study published in the November issue of the journal Aging showed minimal metabolic side effects after continuous, long-term treatment with encapsulated rapamycin in a marmoset (monkey) model. Research results lead to efficacy study.
9-Feb-2016 10:00 AM EST Add to Favorites